<DOC>
	<DOCNO>NCT02980757</DOCNO>
	<brief_summary>The main purpose study assess comparative bioavailability two test formulation Gliclazide 120 mg Modified Release tablet ( 120 mg gliclazide per modify release tablet ) Manufactured By Indeus Life Sciences Pvt . Ltd. , Mumbai India ( An Affiliate Of Disphar International B.V. , The Netherlands ) Relative To DIAMICRON MR® 60 mg 2 × ( 60 mg gliclazide per modify release tablet ) Of Les Laboratories Servier Industrie , France 15 healthy adult subject fasting condition . The second aim ass safety subject determine pharmacokinetic data .</brief_summary>
	<brief_title>Bioequivalence Study Gliclazide 120 mg Modified Release Tablets</brief_title>
	<detailed_description />
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Age 18 50 year , inclusive Body Mass Index ( BMI ) range within 18.5 30.0 Kg/m2 . Subject known allergy drug investigation ingredient related drug . Medical demographic perform longer two week initiation clinical study significant deviation normal range . Results laboratory test outside normal range except HbA1c test outside reference range Hb RBC indices deviation outside 5 % reference range . Acute infection within one week precede first study drug administration . History drug alcohol abuse . Subject heavy smoker ( 10 cigarette per day ) . Subject agree take prescription nonprescription drug within two week precede first study drug administration end study . Subject agree take vitamin take nutritional purpose within two day first study drug administration end study . Subject special diet ( example subject vegetarian ) . Subject consumes large quantity alcohol beverage contain methylxanthines e.g . caffeine ( coffee , tea , cola , chocolate etc ) . Subject agree consume beverage food contain alcohol 48 hour prior study drug administration donate last sample respective period . Subject agree consume beverage food contain methylxanthines e.g . caffeine ( coffee , tea , cola , chocolate etc . ) 24 hour prior study drug administration end confinement period . Subject agree consume beverage food contain grapefruit 7 day prior first study drug administration donate last sample study . Subject history severe disease direct impact study . Participation bioequivalence study clinical study within last 80 day first study drug administration . Subject intend hospitalize within 3 month first study drug administration . Subjects donate blood derivative past 3 month completion study , would donate 1250 ml 120 day , 1500 ml 180 day , 2000 ml 270 day , 2500 ml blood 1 year . The subject pregnant female ( positive urine blood pregnancy test ) lactate female . Subject history significant asthma , peptic gastric ulcer , sinusitis , pharyngitis , renal disorder ( impaired renal function ) , hepatic disorder ( impaired hepatic function ) , cardiovascular disorder , neurological disease epilepsy , haematological disorder diabetes , psychiatric , dermatologic immunological disorder Subject engage strenuous exercise least one day prior dose till last sample respective period . Subject screen examination pulse outside normal range ( 60100 beat per minute ) body temperature outside normal range ( 36.437.7 ○C ) respiratory rate outside normal range ( 1420 breath per minute ) sit blood pressure le 100/60 mm Hg equal 140/90 mm Hg . Subject history difficulty swallow gastrointestinal disease could affect drug absorption . Subject history presence Diabetic ketoacidosis , without coma , Type1 diabetes , renal insufficiency hepatic insufficiency . Fasting blood sugar screen less 3.33 mmol/L . Subject diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>